SmartTRAK hosted a tour, dinner reception and briefing at Gothenburg's Universeum before EWMA 2019. Attendees were treated to a private tour of the Universeum and the Ocean Zone prior to dinner and the briefing, entitled Trends, Opportunities and Innovations in Advanced Wound Care, with a special focus on the European market.
OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.
Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.
What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?
To have a presence in the entire US HA market, OrthogenRx aims to provide...
Topics: Regenerative Medicine
Elise Wolf, SmartTRAK's Senior Analyst, Computer Assisted Surgery, will be representing SmartTRAK at CAOS International 2019, the 19th Annual Meeting of the International Society for Computer Assisted Orthopaedic Surgery, to be held in New York, June 19-22 at the Midtown Hilton.
Elise, with bachelor's and master's degrees in bioengineering, designed biologically inspired robots for the Department of Defense at a spin-off of Carnegie Mellon University. After robotics, she transitioned to the medical device industry and has more than 15 years of experience in product development, marketing, and business development consulting in emerging medical device technologies and orthopedics. Elise has worked with BioMedGPS since 2009 as a SmartTRAK Senior Analyst covering orthopedics and Computer-Assisted Surgery.
You can view Elise's intro video below...
Frederique Buntoum (aka Freddy), SmartTRAK's Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules, will be representing SmartTRAK at TOBI 2019, the Tenth Annual PRP & Regenerative Medicine Symposium in Chicago, IL, June 6-8.
You can view Freddy's intro video below...
Dr. Ronald Baxter of Baylor University and Spectral MD, discusses the Spectral MD DeepView Wound Imaging System in predicting DFU wound healing utilizing artificial intelligence in an interview with SmartTRAK.
Spectral MD has developed the DeepView Wound Imaging System to utilize real-time data and artificial intelligence to predict wound healing. The Company has seen initial success in burn treatment and is now moving into validation of their system for diabetic foot ulcers (DFUs) with the goal to predict a wound’s healing potential at the initial clinical visit.
To learn more about Spectral MD’s multi-spectral imaging system, DeepView; the pilot DFU study to analyze the predictive qualities of its artificial intelligence deep learning program, and the company’s plans moving forward; SmartTRAK interviewed Dr. Ronald Baxter, of Baylor University and Spectral MD.
A transcript of SmartTRAK’s interview with Dr. Baxter is below. To view the interview recorded live at SAWC Spring 2019, click on the following video.
Topics: Advanced Wound Care
The market benefited from easier comps against Q118’s nasty flu season which prompted hospitals across the US to postpone surgeries. But SmartTRAK does not believe the bump in growth in the face of easy comps signals a strengthening recon market. Looking back on a 2-yr basis, the market appears to have decelerated 50 bps which suggests an accompanying slow down in the number of procedures taking place early in the year. Wells Fargo’s Larry Biegelsen speculates that...
Among the many topics covered in the Q119 Total Joints Market Recap are:
Topics: Orthopedics-Total Joints
SmartTRAK interviews Arthrosurface CEO Steve Ek about the Company’s newest shoulder system, the OVOMotion, and what differentiates it from other current and emerging shoulder systems
The orthopedic industry has sharpened its focus on value-based care. Health care providers are looking for technologies that maximize care, reduce costs and increase efficiencies, while patients are seeking affordable treatment options that will restore their function and improve their quality of life.
At the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, Arthrosurface CEO Steve Ek, Dr. Greg Nicholson, Rush University Medical Center, and Dr. Anthony Miniaci, Cleveland Clinic, discussed the Company’s newest shoulder implant system, the OVOMotion stemless shoulder, and its value proposition for both health care providers and patients in an interview with SmartTRAK.
(This is Part 2 of SmartTRAK’s interview with Arthrosurface. Be sure to see Part 1 - "Arthrosurface Takes Aim at Patellofemoral Pain" - in which Arthrosurface discusses their new patellofemoral joint implant, the Wave Kahuna.)
Topics: Orthopedics-Total Joints
The SmartTRAK analyst team is expanding and we are looking for an experienced and motivated individual who would like to manage one or more of our Advanced Wound Care modules, with a focus on the European markets. As you know, all of our SmartTRAK analysts are former marketing, business development or competitive intelligence professionals with one of the major medical device manufacturers and, in fact, most have come to us via recommendations from our subscribers. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add to the SmartTRAK platform.
Intraoperative neuromonitoring could be a game changer in the field of SCS by elucidating the MOA for current and emerging SCS waveforms and stimulation patterns. But will it improve outcomes? To find out more, SmartTRAK interviewed Steven Falowski, MD at NANS 2019.Steven Falowski, MD, Secretary of the Board for the North American Neuromodulation Society (NANS), discusses the latest research on the use of intraoperative neuromonitoring during spinal cord stimulation (SCS) in an interview with SmartTRAK at the NANS 22nd annual meeting held Jan. 17-20, 2019 in Las Vegas.
Historically, pain specialists have always placed spinal cord stimulators in awake patients for safety reasons and to confirm the therapy is adequately covering painful areas. However, Dr. Falowski says there’s been a paradigm shift where both pain physicians and surgeons alike are now using intraoperative neuromonitoring to place SCS systems for both percutaneous electrodes and paddle leads in asleep patients to more accurately localize the spinal cord midline and to improve intraoperative electrode placement and pain coverage...
Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny
After a sluggish start of the year, the US Joint Fluid market gained steam during the quarter as demand and volumes picked up in several market segments in spite of intense competitive pricing pressures. Revenues were within SmartTRAK’s projected range with a marginal decline of -0.3% YoY according to the recently published SmartTRAK Financial Dashboard.
For Q119, the 3-injection segment accounted for 44.6% of the US Joint Fluid market, followed by single-injection products at 41.5%, the 5-injection segment at 12.9% and rounding up the market with the 2-injection segment at 1.1%, according to SmartTRAK Financial Dashboard results. The single-injection segment showed good recovery from last year driven by increased adoption of newer products and/or sales expansion measures by some suppliers. The 3-injection segment was down in the low single digits during Q119 owing to continued and fierce pricing competition. The 5-injection segment showed no reprieve from its downward trend, declining...
Among the many topics covered in the Q119 US Joint Fluid Market Recapare: